LIGAND PHARMACEUTICALS INC Insider Trading for March 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for March 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 2018 | LGND | LIGAND PHARMACEUTI ... | Sabba Stephen L | Director | Sell | S | 180.73 | 622 | 112,414 | 26,363 | 27 K to 26.4 K (-2.30 %) |
| Mar 09 2018 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 176.48 | 4,000 | 705,899 | 79,334 | 83.3 K to 79.3 K (-4.80 %) |
| Mar 09 2018 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 174.88 | 3,500 | 612,095 | 83,334 | 86.8 K to 83.3 K (-4.03 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Option Exercise | M | 10.12 | 3,335 | 33,750 | 0 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Sell | S | 160.90 | 3,335 | 536,604 | 20,956 | 24.3 K to 21 K (-13.73 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Buy | M | 10.12 | 3,335 | 33,750 | 24,291 | 21 K to 24.3 K (+15.91 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 159.01 | 16,050 | 2,552,111 | 16,050 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 165.87 | 550 | 91,229 | 14,215 | 14.8 K to 14.2 K (-3.73 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,004 | 0 | 14,765 | 12.8 K to 14.8 K (+15.70 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 3,074 | 0 | 12,761 | 9.7 K to 12.8 K (+31.73 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | A | 159.01 | 9,292 | 1,477,521 | 9,292 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 165.87 | 392 | 65,021 | 27,583 | 28 K to 27.6 K (-1.40 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 1,136 | 0 | 27,975 | 26.8 K to 28 K (+4.23 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 1,780 | 0 | 26,839 | 25.1 K to 26.8 K (+7.10 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 159.01 | 41,392 | 6,581,742 | 41,392 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 165.87 | 2,982 | 494,624 | 107,419 | 110.4 K to 107.4 K (-2.70 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 6,015 | 0 | 110,401 | 104.4 K to 110.4 K (+5.76 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 7,928 | 0 | 104,386 | 96.5 K to 104.4 K (+8.22 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 159.01 | 20,274 | 3,223,769 | 20,274 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 165.87 | 1,457 | 241,673 | 101,201 | 102.7 K to 101.2 K (-1.42 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 2,940 | 0 | 102,658 | 99.7 K to 102.7 K (+2.95 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 3,883 | 0 | 99,718 | 95.8 K to 99.7 K (+4.05 %) |